In February, the drugmakers reported that the vaccine candidate was effective in adults after a three-dose series. Pfizer and Valneva also tested the vaccine in children ages 5-17, finding the vaccine was more immunogenic in adult trial participants, according to an April 26 news release.
The drugmakers will include pediatric participants in their phase 3 trial, which is expected to begin in the third quarter of 2022.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
